IRS1 and melanoma: Since, at present, anti‐cancer drugs targeting IRS‐1 protein are not available (Reuveni et al., 2013), our data may represent preclinical proof of concept for miR‐126‐based direct targeting of IRS‐1, increasing the possible role of this miR in cancer therapy, including drug‐resistant melanoma.